Mayflower Financial Advisors, LLC Crispr Therapeutics Ag Transaction History

Mayflower Financial Advisors, LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 02, 2024	BUY	$51.17 - $68.18 $9,824 - $13,090	192 Added 1.44%	13,558 $732,000
Q1 2024 Apr 29, 2024	BUY	$60.67 - $89.12 $47,322 - $69,513	780 Added 6.2%	13,366 $911,000
Q4 2023 Jan 22, 2024	BUY	$38.62 - $72.18 $308 - $577	8 Added 0.06%	12,586 $787,000
Q3 2023 Oct 12, 2023	SELL	$45.39 - $59.0 $363 - $472	-8 Reduced 0.06%	12,578 $570,000
Q1 2023 Apr 12, 2023	SELL	$41.0 - $56.12 $1,517 - $2,076	-37 Reduced 0.29%	12,586 $569,000
Q4 2022 Jan 25, 2023	BUY	$39.19 - $65.67 $494,695 - $828,952	12,623 New	12,623 $0
Q3 2022 Oct 19, 2022	BUY	$61.1 - $83.78 $772,059 - $1.06 Million	12,636 New	12,636 $29,000
Q2 2022 Jul 15, 2022	SELL	$43.23 - $73.83 $14,784 - $25,249	-342 Reduced 2.64%	12,636 $28,000
Q1 2022 Apr 21, 2022	BUY	$53.19 - $79.24 $690,299 - $1.03 Million	12,978 New	12,978 $50,000

490

58M

1.1M

1.9M

Ticker CRSP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 78,009,296
Market Cap $3.23B
Description
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA....

Get notified when there are updates to the investment portfolio of Mayflower Financial Advisors, LLC, based on Form 13F filings with the SEC.

Stay updated on Mayflower Financial Advisors, LLC with notifications on news.